Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor-Derived Extracellular Vesicle Proteomics Enables Precise Ovarian Cancer Liquid Biopsy

ABSTRACT: Ovarian cancer (OC) remains one of the most lethal gynecological malignancies, and effective non-invasive biomarkers for early diagnosis, postoperative monitoring, and prognosis assessment are still limited. Serum CA125, the current standard biomarker for OC, has limited diagnostic accuracy, particularly in early-stage disease. Cancer-derived extracellular vesicles (EVs) carry tumor-specific proteomic information and represent promising biomarkers; however, their sensitive and specific isolation from complex biological fluids remains challenging. In this project, we developed BP-EVlent, a novel approach that combines polyethylene glycol (PEG)-based precipitation with CA125 immunoaffinity capture to precisely isolate plasma CA125-positive EVs from patients with OC. The performance of BP-EVlent was evaluated using data-independent acquisition mass spectrometry (DIA-MS)-based proteomic analysis of plasma samples from healthy controls (HC), preoperative OC patients (OC-pre), and postoperative OC patients (OC-post

ORGANISM(S): Homo Sapiens

SUBMITTER: Xianzhong Cheng

PROVIDER: PXD080966 | iProX | Mon Jul 13 00:00:00 BST 2026

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

OCaMIR a non-invasive early diagnostic test for ovarian cancer: A multi-cohort retrospective and prospective analysis

Project description:Owing to the lack of effective screening tools and early detection biomarkers, ovarian cancer (OC) still remains as a deadly disease with highest mortality among other gynecological cancers. So far there have been no attempts to discover biomarkers using early stage OC patients. MicroRNAs (miRNAs) have been recognized as great tool to develop non-invasive biomarkers in various cancers including ovarian cancer.

2020-03-06 | GSE127873 | GEO

Redefined complement C3c structures have significant increase in the plasma of ovarian cancer patients

Project description:Ovarian cancer (OC) ranks as the third most common gynecological cancer. Like other cancers, there still a need for effective biomarkers. To explore if plasma proteolytic products could serve as biomarkers, we devised a platform incorporating CyDye labeling, macroporous reversed-phase liquid chromatography, reducing/non-reducing SDS-PAGE, and fluorescence imaging. With paired preoperative and postoperative plasma samples, our analyses revealed a circulating complement C3 derivative present only at the disease state. This 145-kDa species under non-reducing condition split into 72-, 39-, and 29-kDa fragments upon reduction, reminiscent of the C3c structure. Mass spectrometric analyses showed multiple C-terminal ends in the C3c α’1 fragment, which were used differently among OC patients. The variety of ends were also observed in serum samples prepared using various complement activators, redefining C3c as a mix of multiple molecular entities. A commercialized ELISA assay targeting only the canonical C3c showed a strong correlation between increased plasma levels and the OC occurrence and pro-gression. Our results suggest that plasma proteolysis in complement deactivation is involved in ovarian tumorigenesis, and the resulting protein changes may help develop next-generation cancer biomarker.

2025-05-26 | PXD057890 | Pride

Profiling the metabolome of uterine fluid for early detection of ovarian cancer

Project description:<p>Ovarian cancer (OC) causes high mortality in women because of ineffective biomarkers for early diagnosis. Here, we perform metabolomics analysis on an initial training set of uterine fluid from 96 gynecological patients. A seven-metabolite-marker panel consisting of vanillylmandelic acid, norepinephrine, phenylalanine, beta-alanine, tyrosine, 12-S-hydroxy-5,8,10-heptadecatrienoic acid and crithmumdiol is established for detecting early-stage OC. The panel is further validated in an independent sample set from 123 patients, discriminating early OC from controls with an area under the curve (AUC) of 0.957 (95% confidence interval [CI], 0.894-1.000). Interestingly, we find elevated norepinephrine and decreased vanillylmandelic acid in most OC cells, resulting from excess 4-hydroxyestradiol that antagonizes the catabolism of norepinephrine by catechol-O-methyltransferase. Moreover, exposure to 4-hydroxyestradiol induces cellular DNA damage and genomic instability that could lead to tumorigenesis. Thus, this study not only reveals metabolic features in uterine fluid of gynecological patients but also establishes a noninvasive approach for the early diagnosis of OC. </p>

2023-03-06 | MTBLS4861 | MetaboLights

Plasma extracellular vesicle miRNA profiling in cervical cancer patients and healthy controls

Project description:Cervical cancer (CC) is a malignancy characterized by persistent HPV infection and tumor microenvironment remodeling. To explore the molecular characteristics of plasma extracellular vesicles (EVs) in CC, we performed miRNA sequencing on plasma EVs from 3 CC patients and 3 healthy controls. Differentially expressed miRNAs were identified, revealing potential biomarkers and providing insights into early diagnosis and therapeutic intervention.

2026-01-26 | GSE310070 | GEO

Comprehensive analysis of circulating microRNAs in plasma of patients with pituitary adenomas

Project description:Background: Circulating miRNAs in pituitary adenoma would help patient care especially in non-functioning adenoma cases as minimally invasive biomarkers of tumor recurrence and progression. Aim: Our aim was to investigate plasma miRNA profile in patients with pituitary adenoma. Materials and Methods: 149 plasma and extracellular vesicle (preoperative, early- and late postoperative) samples were collected from 45 pituitary adenoma patients. Adenomas were characterized based on anterior pituitary hormones and transcription factors by immunostaining. MiRNA next generation sequencing was performed on 36 samples (discovery set). Individual TaqMan assay was used for validation on extended sample set. PA tissue miRNAs were evaluated by TaqMan array and literature data. Results: Global downregulation of miRNA expression was observed in plasma samples of pituitary adenoma patients compared to normal samples. Expression of 29 miRNAs and isomiR variants were able to distinguish preoperative plasma samples and normal controls. MiRNAs with altered expression in both plasma and different adenoma tissues were identified. 3, 7 and 66 miRNAs expressed differentially between preoperative and postoperative plasma samples in growth hormone secreting, FSH/LH+ and hormone-immunonegative groups, respectively. MiR-143-3p was downregulated in late- but not in early postoperative plasma samples compared to preoperative ones exclusively in FSH/LH+ adenomas. Plasma level of miR-143-3p discriminated these samples with 81.8% sensitivity and 72.3% specificity (AUC=0.79; p=0.02). Conclusions: Differentially expressed miRNAs in pituitary adenoma tissues have low abundance in plasma minimizing their role as biomarkers. Plasma miR-143-3p decreases in patients with FSH/LH+ adenoma indicated successful surgery, but its application for evaluating tumor recurrence needs further investigation.

2019-05-21 | GSE131483 | GEO

RNA-Seq of Tissue, Plasma and Urinary Extracellular Vesicles of Prostate Cancer patients

Project description:We performed RNA-Seq analysis of plasma and urinary EVs collected before and after radical prostatectomy, and matched tumor and normal prostate tissues of 10 patients with prostate cancer. To identify putative cancer-derived RNA biomarkers, we searched for RNAs that were overexpressed in tumor as compared to normal tissues, present in the pre-operation EVs and decreased in the post-operation EVs in each RNA biotype.

2022-11-16 | E-MTAB-11910 | biostudies-arrayexpress

OC-MS/MS - HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer

Project description:Ovarian cancer (OC) is the most lethal gynecological carcinoma because of the lack of early diagnostic markers and effective drug targets. Discovery of new therapeutic targets in OC to improve the treatment outcome is urgently needed. Patients with recurrent EOC after initial therapy have few treatment options that greatly compromises their quality of life and life expectancy. Discovery of new therapeutic targets in EOC to improve the treatment outcome is urgently needed. Proteomic analysis is one of the approaches to identify therapeutic targets in OC.

2019-09-09 | PXD013811 | Pride

Human multiethnic radiogenomics reveals low-abundancy microRNA signature in plasma-derived extracellular vesicles for early diagnosis and molecular subtyping of pancreatic cancer

Project description:Pancreatic cancer (PC) is a highly lethal malignancy, and its early diagnosis remains a clinical challenge. Extracellular vesicles (EVs) derived from patient plasma contain diverse RNA species that may serve as minimally invasive biomarkers. In this study, we performed RNA sequencing (RNA-seq) on EVs isolated from plasma samples of 85 individuals, including 65 patients with pancreatic cancer and 20 patients with benign pancreatic diseases. The benign group consisted of 10 intraductal papillary mucinous neoplasms (IPMN) and 10 chronic pancreatitis (CP) cases. Our aim was to identify differentially expressed RNA signatures in plasma-derived EVs that can distinguish pancreatic cancer from benign conditions. This dataset provides a valuable resource for biomarker discovery in liquid biopsy-based diagnosis of pancreatic cancer.

2025-08-10 | GSE304572 | GEO

MiRNA signatures associated with lung involvement in systemic sclerosis (Small RNA-Seq)

Project description:There is a pressing need to identify early biomarkers of lung involvement in systemic sclerosis (SSc) to start as soon as possible antifibrotic therapy. We aimed to identify extracellular vesicle-derived microRNAs (EV-miRNAs) that are differentially expressed between SSc patients with and without interstitial lung disease (ILD) and explore their diagnostic value. Small EVs derived from plasma were isolated from 20 well-characterised SSc patients with ILD (SSc-ILD, n=10), without ILD (SSc-no ILD, n=10) and 10 matched healthy subjects (HS). Small RNA sequencing was used to identify sEV-miRNAs associated to SSc-ILD.

2024-09-15 | E-MTAB-14290 | biostudies-arrayexpress

Role of plasma extracellular vesicles in lung cancer pre-metastatic niche formation

Project description:Lung cancer is the deadliest cancer worldwide, primarily due to metastatic spread. Tumor-derived extracellular vesicles (EVs) play a crucial role in the formation of pre-metastatic niches (pMNs), facilitating the spread and expansion of circulating cancer cells. So far, little is known about the role of plasma EVs in lung cancer pMN formation. We aim to elucidate the EV role in pMN formation and identify new prognostic biomarkers for early-stage lung cancer.Plasma-derived EVs were obtained by ultracentrifugation from early-stage lung cancer patients who survived at 5 years (ESA-EVs) and patients who died within two years (ESD-EVs). Heavy-smokers cancer free individuals were used as control (HS-EVs). Functional in vitro experiments on endothelial cells were carried out using 15ug of EVs from different groups for 48h. We observed that ESD-EVs significantly induced a “pro-inflammatory” endothelial phenotype. Characterization of ESD-EV revealed higher levels of miR-29 and C4a compared to ESA and HS-EVs. Concomitant miR-29 transfection and C4a administration in endothelial cells recapitulated the pro-inflammatory activation observed with EVs. In conclusion, we showed that plasma EVs could drive lung pMN formation, conferring a pro-inflammatory phenotype to endothelial cells to favour metastasis outgrowth

2026-07-15 | GSE302138 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data